GlassScriptPhysician profile
Diego A Maldonado
NPI 1568673630
$254,181.51
in general payments reported to CMS, 2019-2025
30 companies · $32K in 2025
The $32K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $14K · 2021: $21K · 2022: $36K · 2023: $78K · 2024: $52K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Travel and Lodging: $9,643 · Consulting Fee: $8,700 · Food and Beverage: $7,490 · Education: $4,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,696.50 |
| Travel and Lodging | $9,643.46 |
| Consulting Fee | $8,700.00 |
| Food and Beverage | $7,490.37 |
| Education | $4,380.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $116,764.08 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $59,065.88 | 2021-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $28,566.02 | 2019-2024 | Yupelri, Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $27,452.37 | 2019-2025 | |
| United Therapeutics Corporation | $6,608.95 | 2021-2025 | Tyvaso, Tyvaso |
| Intuitive Surgical, INC. | $4,700.07 | 2025 | |
| Pulmonx Corporation | $4,004.27 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Johnson & Johnson Health Care Systems INC. | $2,900.00 | 2023-2025 | Veletri, Uptravi, Opsumit |
| Ethicon INC. | $852.52 | 2020-2025 | Monarch Platform |
| Veran Medical Technologies, INC. | $737.16 | 2019-2020 | |
| Boston Scientific Corporation | $603.40 | 2021-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $518.11 | 2020-2025 | Fasenra, Airsupra |
| Viatris Specialty LLC | $337.00 | 2025 | Yupelri |
| Amgen INC. | $182.49 | 2023-2025 | Tezspire |
| Verona Pharma, INC. | $149.31 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $114.30 | 2022 | |
| Pfizer INC. | $98.89 | 2019 | |
| Insmed, INC. | $84.48 | 2020-2025 | Arikayce |
| Inspire Medical Systems, INC. | $71.83 | 2024 | Inspire |
| Covidien LP | $71.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $66.91 | 2024 | Dupixent |
| Genzyme Corporation | $42.33 | 2023 | |
| Genentech USA, INC. | $39.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.18 | 2024 | Glassia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.30 | 2023 | Lifevest |
| Penumbra, INC. | $23.66 | 2024 | Indigo System |
| Merck Sharp & Dohme LLC | $22.18 | 2024 | Winrevair |
| Abbvie INC. | $21.26 | 2022 | |
| Icu Medical INC | $16.67 | 2024 | Tracheostomy |
| Ambu INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.